English
Français
>>
>>
News
Agenda
Subscribe to news
Get to know AsiDNA
View corporate presentation
BECOME A PARTNER
BECOME A SHAREHOLDER
NEWS >
Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook
New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors
AGENDA >
Investor meetings around the JP Morgan Healthcare Conference 2018
January 8-11, 2018
